Buprenorphine is available under several brand names, primarily for the treatment of opioid use disorder and moderate to severe pain. The most well-known brand name for buprenorphine used in opioid addiction treatment is Suboxone, which combines buprenorphine with naloxone [1][2]. Other formulations and brand names exist for different indications and delivery methods.
What is Buprenorphine Used For?
Buprenorphine is prescribed for two main purposes: managing moderate to severe pain and treating opioid use disorder [1]. For pain management, it is available in various forms, including injections and transdermal patches [3]. In the treatment of opioid dependence, it functions as a partial opioid agonist, helping to reduce withdrawal symptoms and cravings [1].
What is the Difference Between Suboxone and Zubsolv?
Both Suboxone and Zubsolv contain buprenorphine and naloxone, and both are used for treating opioid use disorder. Zubsolv is a sublingual tablet that is formulated for faster absorption and may have a different taste profile compared to Suboxone films [4]. The specific choice between them can depend on physician preference and patient response.
How Does Buprenorphine Treat Pain?
When used for pain management, buprenorphine is typically administered via injection or a transdermal patch that slowly releases the medication over a period of time. It binds to opioid receptors in the brain to block pain signals [3].
What Are Other Buprenorphine Brand Names?
Beyond Suboxone and Zubsolv, other brand names for buprenorphine products include Subutex (buprenorphine only, for opioid dependence), Belbuca (buccal film for pain), and Butrans (transdermal patch for pain) [1][2][5]. The presence of naloxone in formulations like Suboxone is intended to deter misuse by injection, as naloxone can precipitate withdrawal symptoms if the medication is abused [1].
When Do Buprenorphine Patents Expire?
Patent expiries for buprenorphine products vary depending on the specific formulation, indication, and manufacturing company. DrugPatentWatch.com provides detailed information on patent status and expiry dates for pharmaceuticals. For example, patents related to buprenorphine formulations and their use in treating opioid dependence or pain have been subject to numerous applications and potential challenges over time [6]. Information on the patent landscape for specific buprenorphine products can be found on specialized drug patent tracking websites.
Who Makes Buprenorphine Products?
Different pharmaceutical companies manufacture and market various buprenorphine products. For instance, Suboxone was originally developed by Reckitt Benckiser Pharmaceuticals, while Zubsolv is marketed by Orexo US Inc. [4][7]. Other companies produce generic versions or different brand-name formulations for pain management [3].
What Are the Risks Associated with Buprenorphine?
Like other opioids, buprenorphine carries risks, including the potential for dependence and addiction, although it is considered to have a lower abuse potential than full opioid agonists when used as prescribed for opioid use disorder [1]. Common side effects can include nausea, constipation, headache, and drowsiness. When combined with naloxone, misuse can lead to precipitated withdrawal [1][3].
Can Generic Buprenorphine Be Used?
Yes, generic versions of buprenorphine products, including those for pain management and opioid use disorder, are available. Generic buprenorphine can offer a more affordable treatment option. However, for formulations combining buprenorphine and naloxone, bioequivalence studies are crucial to ensure that generic versions perform comparably to the brand-name drugs.
What Is the Patient Outlook for Buprenorphine Treatment?
For individuals with opioid use disorder, buprenorphine treatment, particularly with medications like Suboxone or Zubsolv, has been shown to be effective in reducing illicit opioid use, overdose deaths, and improving retention in treatment [1][4]. For pain management, its effectiveness and duration of relief depend on the specific product, dosage, and individual patient response [3].
Sources
[1] National Institute on Drug Abuse. (2023). Buprenorphine: Treatment Options.
[2] U.S. Food and Drug Administration. (n.d.). Medication Assisted Treatment (MAT) - Approved Medications.
[3] National Institute on Drug Abuse. (2020). Opioids.
[4] Orexo. (n.d.). Zubsolv® (buprenorphine and naloxone) sublingual tablets.
[5] Healthline. (2023). Buprenorphine (Sublingual and Transmucosal Routes).
[6] DrugPatentWatch.com. (n.d.). Buprenorphine Patent Information.
[7] Indivior. (n.d.). Our Products.